Добірка наукової літератури з теми "Chemotherapy-induced febrile neutropenia"
Оформте джерело за APA, MLA, Chicago, Harvard та іншими стилями
Ознайомтеся зі списками актуальних статей, книг, дисертацій, тез та інших наукових джерел на тему "Chemotherapy-induced febrile neutropenia".
Біля кожної праці в переліку літератури доступна кнопка «Додати до бібліографії». Скористайтеся нею – і ми автоматично оформимо бібліографічне посилання на обрану працю в потрібному вам стилі цитування: APA, MLA, «Гарвард», «Чикаго», «Ванкувер» тощо.
Також ви можете завантажити повний текст наукової публікації у форматі «.pdf» та прочитати онлайн анотацію до роботи, якщо відповідні параметри наявні в метаданих.
Статті в журналах з теми "Chemotherapy-induced febrile neutropenia"
Temblett, Paul. "Chemotherapy-induced febrile neutropenia." Clinical Medicine 8, no. 6 (December 1, 2008): 634.1–634. http://dx.doi.org/10.7861/clinmedicine.8-6-634.
Повний текст джерелаMoe, Myat, and Robert Leonard. "Chemotherapy induced febrile neutropenia." Oncology Times 4, no. 3 (March 2007): 21. http://dx.doi.org/10.1097/01434893-200703000-00019.
Повний текст джерелаSalako, Omolola, Kehinde Sharafadeen Okunade, Adeoluwa Akeem Adeniji, Gabriel Fagbenro, and Oluwasegun Afolaranmi. "Chemotherapy-induced neutropenia among breast cancer patients presenting to a tertiary hospital in Nigeria." Journal of Clinical Oncology 38, no. 15_suppl (May 20, 2020): e12523-e12523. http://dx.doi.org/10.1200/jco.2020.38.15_suppl.e12523.
Повний текст джерелаStrojnik, Ksenija, Ksenija Mahkovic-Hergouth, Barbara Jezersek Novakovic, and Bostjan Seruga. "Outcome of severe infections in afebrile neutropenic cancer patients." Radiology and Oncology 50, no. 4 (December 1, 2016): 442–48. http://dx.doi.org/10.1515/raon-2016-0011.
Повний текст джерелаMarshall, E., and H. Innes. "Chemotherapy induced febrile neutropenia: management and prevention." Clinical Medicine 8, no. 4 (August 1, 2008): 448–51. http://dx.doi.org/10.7861/clinmedicine.8-4-448.
Повний текст джерелаKorpelainen, Sini, Carina Intke, Sari Hämäläinen, Esa Jantunen, Auni Juutilainen, and Kari Pulkki. "Soluble CD14 as a Diagnostic and Prognostic Biomarker in Hematological Patients with Febrile Neutropenia." Disease Markers 2017 (2017): 1–8. http://dx.doi.org/10.1155/2017/9805609.
Повний текст джерелаMurtaza, Hafiz Muhammad, Samra Maryam, Muhammad Shaheen Iqbal, Tariq Ghafoor, Aamir Aslam Awan, and Naeem Farid. "Chemotherapy Induced Neutropenic Fever and Its Response to Empirical Antimicrobial Therapy." Pakistan Armed Forces Medical Journal 72, SUPPL-2 (June 2, 2022): S172–77. http://dx.doi.org/10.51253/pafmj.v72isuppl-2.3079.
Повний текст джерелаMcBride, Ali, Neda Alrawashdh, Trace Bartels, Logan Moore, Daniel Persky, and Ivo Abraham. "Same-day versus next-day pegfilgrastim or pegfilgrastim-cbqv in patients with lymphoma receiving CHOP-like chemotherapy." Future Oncology 17, no. 26 (September 2021): 3485–97. http://dx.doi.org/10.2217/fon-2021-0532.
Повний текст джерелаBal, Abhijit M., and Ian M. Gould. "Empirical antimicrobial treatment for chemotherapy-induced febrile neutropenia." International Journal of Antimicrobial Agents 29, no. 5 (May 2007): 501–9. http://dx.doi.org/10.1016/j.ijantimicag.2006.11.026.
Повний текст джерелаDimitrijević, Jelena, and Marko Stojanović. "Prophylaxis and management of chemotherapy-induced febrile neutropenia: The role of myeloid growth factors." Medicinski podmladak 73, no. 2 (2022): 1–5. http://dx.doi.org/10.5937/mp73-36780.
Повний текст джерелаДисертації з теми "Chemotherapy-induced febrile neutropenia"
Lee, Yee Mei. "Predicting chemotherapy-induced febrile neutropenia outcomes in adult cancer patients: an evidence-based prognostic model." Thesis, 2014. http://hdl.handle.net/2440/83772.
Повний текст джерелаThesis (Ph.D.) -- University of Adelaide, School of Translational Health Science, 2014
Liu, Cheng-Chung, and 劉承忠. "Study on the Use of G-CSF in Breast Cancer Patients for Managing Chemotherapy-induced Febrile Neutropenia." Thesis, 2009. http://ndltd.ncl.edu.tw/handle/58531561954385730376.
Повний текст джерела臺北醫學大學
藥學研究所
97
Rationale Febrile neutropenia (FN) is a serious hematological toxicity of cancer chemotherapy and could be prevented with the prophylactic use of antibiotics and/or granulocyte colony-stimulating factor (G-CSF). G-CSF is hematopoietic growth-stimulating factor, which regulates the proliferation, differentiation and function of hematopoietic cells. G-CSF dose-dependently increases the cell number of circulating neutrophils. Early clinical trials indicated that primary prophylaxis with G-CSF reduces the duration of chemotherapy-induced neutropenia resulting in a 50% reduction in FN, infections, hospitalization, and the use of antibiotics in small cell lung cancer patients. In the study, the rate of FN was reduced from 77% to 40%, with long-term G-CSF treatment started on day 4 and continuing through day 17. Regarding to breast cancer patients, G-CSF as primary prophylaxis administered on days 4 to10 after TAC (adriamycin, paclitaxel, and cyclophosphamide) chemotherapy regimen lead to a reduction of FN risk from 27.5% to 7.5%. Based on the practice guidelines, primary prophylaxis of G-CSF treatment protocol can only be used for high risk patients with FN. Objective G-CSF is relatively expensive medicine. Currently, at the Sun Yat-Sen Cancer Center (SYSCC), G-CSF was prescribed to patients with prior severe neutropenia or FN for only three days due to the regulation of national health insurance (NHI). The main objective of this study was to investigate the rate of FN after primary and secondary prophylaxis of G-CSF in breast cancer patients (n=511); the secondary objectives were to investigate the prescribing pattern of G-CSF at SYSCC and to evaluate the cost-effectiveness of G-CSF use under the regulation of NHI. Study Design We performed a retrospective chart review of breast cancer patients who received chemotherapy or lenograstim at SYSCC during year 2007. The information included in this review were patients’ age, sex, tumor type, dosage of chemotherapy, the dose and duration of G-CSF, history of FN and neutropenia, and the length and cost of hospitalization due to FN. Then, we divided patients into three groups according to the risk of FN on received chemotherapy regimen, high (>20%), intermediate (10-20%), low (<10%), to find out the FN risk in different groups and also the regimen of lenograstim use. Furthermore, we focus on the FN risk and regimen of G-CSF use in patients with breast cancer who received chemotherapy regimen of TAC, ATC, and CAF. All these data will be analyzed and compared with the current literature to evaluate the efficacy and cost-effectiveness of G-CSF. Finally, a decision-analysis model was constructed from a health insurer’s perspective to evaluate the cost-effectiveness by considering direct medical costs only. The data required for the decision-analysis model were obtained from the medical literature and data from SYSCC. Results Between January 2007 and December 2007, 511 breast patients who received both chemotherapy and lenograstim at SYSCC were enrolled in the study. Patients in the high risk group (TAC) did not have significantly reduced rate of FN (33.33%) after receiving lenograstim treatment for 3 days. Furthermore, the three common chemotherapy regimens for the treatment of breast cancer were (i) sequential treatment with doxorubicin, paclitaxel, and cyclophosphamide (ATC), (ii) combined treatment with doxorubicin, docetaxel, and cyclophosphamide (TAC), and (iii) treatment with cyclophosphamide, doxorubicin, and 5-fluorouracil (CAF). Comparison of three treatment groups, group TAC (33.33%, with primary prophylaxis G-CSF) was associated with higher FN incidence than ATC (6.66%, with primary prophylaxis G-CSF) and CAF (5.97%, with secondary prophylaxis G-CSF) groups after 3 days lenograstim treatment. And the duration of lenograstim were 3.19 days in CAF group, 6.08 days in ATC group, and 2.95 days in TAC group, respectively. Finally, most of patients in the TAC and CAF groups received only 3 days of G-CSF prophylaxis due to the regulation of national health insurance (NHI). After the cost-effectiveness analysis, the incremental cost-effectiveness ratio (ICER) in comparison of 7-day treatment regimen (according to clinical trials) versus 3-day treatment regimen was unacceptably high (N.T.120,265 per FN episode avoided). Discussion The higher FN incidence in breast cancer patients of high risk chemotherapy regimen after G-CSF prophylaxis may be due to the short duration of G-CSF use. The risks of FN in TAC group of SYSCC and the prior study were 33.33% and 7.5%, respectively. This 5-fold higher risk in the TAC group may be due to the difference in period of G-CSF prophylaxis reducing from 7 days to 3 days in the SYSCC. In ATC group, the risk of FN in the present study (6.66%) was 3 times higher than the report of Citron et al. (2%). Earlier studies indicate the risk of developing FN in patients received CAF chemotherapy are ranging from 2 to 5 % while in the present study the risk was similar (5.97%). The reason of unexpected higher incidence of FN in TAC regimen is unclear, but is highly likely that the decreased efficacy was due to short time period (3 days) of G-CSF treatment. Concluding Remark Based on present results, patients who received chemotherapy of high risk in FN and G-CSF for primary prophylaxis still had the rate of FN 33.33%. The result may be due to the 3-day G-CSF use under the regulation of NHI. Moreover, many patients under 3-day G-CSF regimen may further require another 3-day G-CSF regimen to support the developed neutropenia. Additionally, the cost-effectiveness model provides evidence that 7-day G-CSF regimen is not only cost-effective but also cost-saving in clinical settings. There appeared to be both clinical and economic benefits from prophylaxis with standard administration (7-day) of G-CSF. Therefore, further prospective study should be performed to find out the most appropriate duration of G-SCF use. The result could be provided as an evidence to persuade and modify the reimbursement policy of NHI.
Книги з теми "Chemotherapy-induced febrile neutropenia"
J, Klastersky, ed. Febrile neutropenia. Berlin: Springer, 1997.
Знайти повний текст джерелаKlastersky, J. Febrile neutropenia. London: Springer Healthcare, 2014.
Знайти повний текст джерелаChampigneulle, Benoit, and Frédéric Pène. Pathophysiology and management of neutropenia in the critically ill. Oxford University Press, 2016. http://dx.doi.org/10.1093/med/9780199600830.003.0274.
Повний текст джерелаHowe, Christine K. An assessment of an antibiotic treatment algorithm for chemotherapy-induced febrile neutropenia: prescribing congruence and patient outcomes. 2003, 2003.
Знайти повний текст джерелаЧастини книг з теми "Chemotherapy-induced febrile neutropenia"
Rivera, F., J. I. Mayordomo, M. T. Díaz-Puente, M. P. Lianes, M. López-Brea, E. López, L. Paz-Ares, S. Alonso, and H. Cortés-Funes. "Role of G-CSF and GM-CSF in the treatment of febrile neutropenia induced by chemotherapy ; preliminary results of a randomized trial." In Cancer Treatment An Update, 880–84. Paris: Springer Paris, 1994. http://dx.doi.org/10.1007/978-2-8178-0765-2_186.
Повний текст джерелаYadav, SP, and A. Sachdeva. "Granulocyte Colony-Stimulating Factor (G-CSF) for Chemotherapy-Induced Febrile Neutropenia." In Advances in Pediatrics, 471. Jaypee Brothers Medical Publishers (P) Ltd., 2007. http://dx.doi.org/10.5005/jp/books/10034_51.
Повний текст джерелаYap, Kevin Yi-Lwern. "A Pharmaco-Cybernetics Approach to Patient Safety." In Healthcare Ethics and Training, 1291–310. IGI Global, 2017. http://dx.doi.org/10.4018/978-1-5225-2237-9.ch061.
Повний текст джерелаYap, Kevin Yi-Lwern. "A Pharmaco-Cybernetics Approach to Patient Safety." In E-Health and Telemedicine, 1445–64. IGI Global, 2016. http://dx.doi.org/10.4018/978-1-4666-8756-1.ch073.
Повний текст джерелаYap, Kevin Yi-Lwern. "A Pharmaco-Cybernetics Approach to Patient Safety." In Advances in Healthcare Information Systems and Administration, 179–97. IGI Global, 2014. http://dx.doi.org/10.4018/978-1-4666-4546-2.ch010.
Повний текст джерелаТези доповідей конференцій з теми "Chemotherapy-induced febrile neutropenia"
Tsuchida, Shinpei, Hironobu Tsubouchi, Akiko Kitamura, Nobuhiro Matsumoto, and Masamitsu Nakazato. "Risk factors of febrile neutropenia induced by chemotherapy in lung cancer patients." In ERS International Congress 2016 abstracts. European Respiratory Society, 2016. http://dx.doi.org/10.1183/13993003.congress-2016.pa4842.
Повний текст джерелаMyers, R., B. Higgins, J. Myers, M. Leung, S. Rajagopal, G. Jones, and J. Stakiw. "Chemotherapy Induced Febrile Neutropenia of Docetaxel with Cyclophosphamide (TC) for Adjuvant Therapy of Breast Cancer in the Community – Reality Check." In Abstracts: Thirty-Second Annual CTRC‐AACR San Antonio Breast Cancer Symposium‐‐ Dec 10‐13, 2009; San Antonio, TX. American Association for Cancer Research, 2009. http://dx.doi.org/10.1158/0008-5472.sabcs-09-2092.
Повний текст джерелаWeycker, Derek, Xiaoyan Li, Richard Barron, Hongsheng Wu, Phuong Khanh Morrow, Hairong Xu, Maureen Reiner, Jacob Garcia, Shivani Mhatre, and Gary Lyman. "Abstract P6-10-01: Risk of chemotherapy-induced febrile neutropenia (FN) in patients (pts) with non-metastatic breast cancer (BC) and documented risk factors for FN." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p6-10-01.
Повний текст джерелаMcBride, A., K. Campbell, M. Bikkina, K. MacDonald, I. Abraham, and S. Balu. "Abstract P4-12-07: Cost-minimization of chemotherapy-induced (febrile) neutropenia prophylaxis with biosimilar ZARXIO® over NEUPOGEN®, NEULASTA®, and NEULASTA/ONPRO®: Breast cancer case study." In Abstracts: 2017 San Antonio Breast Cancer Symposium; December 5-9, 2017; San Antonio, Texas. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.sabcs17-p4-12-07.
Повний текст джерелаGascón, Pere, Matti Aapro, Heinz Ludwig, Mario Boccadoro, Carsten Bokemeyer, Matthew Turner, Michael Muenzberg, Ivo Abraham, Kris Denhaerynck, and Karen MacDonald. "Abstract P5-15-19: Prophylaxis of chemotherapy-induced febrile neutropenia with biosimilar filgrastim: Description of patients, treatment patterns and outcomes in the MONITOR-GCSF study in the breast cancer cohort." In Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium; December 9-13, 2014; San Antonio, TX. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.sabcs14-p5-15-19.
Повний текст джерелаWeycker, Derek, Amanda Silvia, Ahuva Hanau, Lois Lamerato, Kathryn Richert-Boe, Manpreet Kaur, Neel Shah, Mark Hatfield, and Gary H. Lyman. "Abstract P2-08-24: Risk of chemotherapy-induced febrile neutropenia (FN) in patients with metastatic cancer of the breast or other sites not receiving colony-stimulating factor prophylaxis (CSF) in US clinical practice." In Abstracts: 2019 San Antonio Breast Cancer Symposium; December 10-14, 2019; San Antonio, Texas. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.sabcs19-p2-08-24.
Повний текст джерела